About OncoSphera
OncoSphera is a Healthcare company. It operates as a technological innovations are developed for cancer patient management using genomics, AI, and cell models. OncoSphera offers products and services including Genomics and AI Services and Cell Model Technology. Its focus areas include Biotechnology, Cancer Research, Personalized Medicine and Artificial Intelligence. Its legal entity in India is OncoSphera Pvt. Ltd (U72100RJ2023PTC090498).
Company details
Technological innovations are created by OncoSphera for the N-of-1 method in cancer patient management, utilizing cell model technologies, genomics, and artificial intelligence to identify optimal therapy combinations tailored to individual patients. This approach addresses complexities in advanced cancer stages, where tumors become metastatic and difficult to treat, by suggesting therapies that are tested externally. As a result, patients are spared from enduring severe side effects during therapy trials, ensuring more precise and personalized treatment strategies are employed.
- SectorsHealthcare
- Email••••••••
- Legal Name Oncosphera Pvt. Ltd
- Date of Incorporation 11 Oct, 2023
- Jurisdiction Lavera Baori, Rajasthan, India
Associated legal entities of OncoSphera
OncoSphera operates through Oncosphera Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Oncosphera Private Limited CIN U72100RJ2023PTC090498 | Active | 11 Oct 2023 | Lavera Baori, Rajasthan | – | – | 3 | View details |
Products & Services of OncoSphera
OncoSphera offers a comprehensive portfolio of products and services, including Genomics and AI Services and Cell Model Technology.
Genomics and artificial intelligence are employed to analyze cancer biology and suggest therapy combinations for individual patients.
Cell model technology is integrated with other methods to test therapy options outside the patient's body, reducing potential side effects.
Board of directors of Oncosphera Private Limited (OncoSphera)
Oncosphera Private Limited is the primary company behind OncoSphera. The board of Oncosphera Private Limited currently have 3 directors; the longest-serving is Sushmita Jha, appointed in 2023.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sushmita Jha DIN 10350888 | Director | 11 Oct 2023 | 3 yrs | Oncosphera Private Limited |
| Vishakha Pareek DIN 10350889 | Director | 11 Oct 2023 | 3 yrs | Oncosphera Private Limited |
| Siddharth Srivastava DIN 10350890 | Director | 11 Oct 2023 | 3 yrs | Oncosphera Private Limited |
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as OncoSphera (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OncoSphera
Technological innovations are created by OncoSphera for the N-of-1 method in cancer patient management, utilizing cell model technologies, genomics, and artificial intelligence to identify optimal therapy combinations tailored to individual patients. This approach addresses complexities in advanced cancer stages, where tumors become metastatic and difficult to treat, by suggesting therapies that are tested externally. As a result, patients are spared from enduring severe side effects during therapy trials, ensuring more precise and personalized treatment strategies are employed.
OncoSphera offers Genomics and AI Services and Cell Model Technology.
OncoSphera operates through Oncosphera Private Limited.
The legal entities of OncoSphera currently have 3 directors, including Sushmita Jha, Vishakha Pareek, Siddharth Srivastava.